Resources for families

• Healthy Living for Families
• Patient and Family Guide to Second Generation Antipsychotics (PDF)
• SGAs, Insulin, Diet and Activity (PDF)
• SGAs, Prolactin, Diet and Activity (PDF)
• SGAs, Triglycerides, Diet and Activity (PDF)
• SGAs, Appetite, Diet and Activity (PDF)
• SGAs, Blood Pressure, Diet and Activity (PDF)
• SGAs, Cholesterol, Diet and Activity (PDF)

Metabolic assessment, screening & monitoring tools

• BC Revised Metabolic Assessment, Screening and Monitoring Tool (2014) (PDF)
• Measurement Guide for Metabolic Assessment, Screening & Monitoring Tool (PDF)

Second generation antipsychotics & metabolic complications

• Metabolic Monitoring Learning Program
  This course provides an overview of first-generation antipsychotic (FGA) and second-generation antipsychotic (SGA) use in BC and Canada as it relates to children and youth. The three modules include a review of current approvals and prescription trends, examine the implications of SGA use and review evidence-informed practices for the monitoring and management of SGAs.
• Evidence-Based Recommendations for Monitoring Safety of Second Generation Antipsychotics in Children and Youth (PDF)
  Evidence-based recommendations for monitoring SGA safety are provided in the guideline.
• First do no Harm: Promoting an Evidence-Based Approach to Atypical Antipsychotic use in Children and Adolescents (PDF)
  Journal article reviewing the evidence for efficacy and metabolic effects of atypical antipsychotics (AAPs), and to propose a metabolic monitoring protocol for AAP use in children and adolescents.
• Increased Prevalence of Obesity and Glucose Intolerance in Youth Treated With Second-Generation Antipsychotic Medications (PDF)
  Journal article comparing the rates of obesity, impaired fasting glucose (IFG), and type 2 diabetes between second-generation antipsychotic (SGA)-treated and -naive youth.
• Management Recommendations for Metabolic Complications Associated with Second Generation Antipsychotic Use in Children and Youth (PDF)
  Previous guidelines have been developed for monitoring for metabolic and neurological complications. This is a complementary set of treatment recommendations if abnormal measurements or results are encountered.
• Treatment recommendations for extrapyramidal side effects associated with second generation anti-psychotic use in children and youth (PDF)
  Journal article providing guidance to clinicians on the clinical management of extrapyramidal side effects of second-generation antipsychotics.
• Treatment Recommendations for Metabolic Complications Associated with SGA Use in Children: A Quick Reference Guide (PDF)